Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GW Pharma Publishes More Positive Data for Cannabis Drug

By Ryan Bushey | September 27, 2016

GW Pharmaceuticals continued its streak of good luck.

The London-based drug maker posted another set of positive phase 3 data for Epidiolex, an experimental cannabis drug being used to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome (LGS).

Different doses yielded different results, according to GW’s announcement. A 20-mg dosage of the drug taken daily contributed to a 42 percent drop in monthly seizures compared to 17 percent for participants taking placebo. Volunteers taking 10mg a day experienced an estimated 37 percent monthly drop in seizures while the placebo portion of this group stayed at 17 percent.

Common adverse events varied between diarrhea and upper respiratory infections, but the pattern remained consistent with previous trials. Overall, the drug was generally well tolerated.

This new data bodes well for GW, reported Reuters.

A trove of positive data like this could help the 18-year-old firm support its case for regulatory approval potentially making Epidiolex the first U.S. approved prescription drug extracted from cannabis.

The U.S. Food and Drug Administration has already granted Epidiolex an orphan drug designation for LGS and a similar disorder called Dravet syndrome giving GW a formidable therapeutic candidate in a market that is just starting to develop.

A marketing application is expected to be submitted to the FDA in the first half of next year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE